Markers of environmental enteric dysfunction are associated with changes in pharmacokinetics of praziquantel in preschool age children with Schistosoma mansoni infection in Albertine region of Uganda
- 1MRC/UVRI and LSHTM Uganda Research Unit
Abstract
IntroductionPraziquantel (PZQ) is the only widely available chemotherapy that is effective against all species of schistosomes. Environmental enteric dysfunction (EED) is an acquired intestinal disorder of altered gut function whose effect on drug pharmacokinetics has not been directly explored.
MethodsPreschool-age children infected with S. mansoni were randomized to receive 40mg/kg or 80mg/kg of crushed PZQ tablets. Plasma PZQ concentrations were quantified using ultra-high performance liquid chromatography mass spectrometry. Maximum concentration (Cmax), time to Cmax (Tmax) and area under the curve (AUC) of PZQ were calculated. Biomarkers of intestinal inflammation (stool calprotectin), epithelial damage (plasma Intestinal Fatty Acid Binding Protein (IFABP)), permeability (urine lactulose:mannitol (LM) ratio and alpha-1 antitrypsin (AAT)), microbial translocation (plasma Endotoxin core antibodies (EndoCAb), systemic inflammation (plasma C-reactive protein (CRP)), and presence of faecal occult blood (FOB) were measured. Using linear regression, we assessed association of AUC, Cmax, Tmax and R- to S-PZQ exposure with each biomarker, adjusting for dose, age, and sex.
ResultsOf the 184 participants included in the final analysis, 91 received 40mg/kg and 93 received 80mg/kg of PZQ. The Tmax was associated with LM ratio ({beta}=0.06, 95% CI 0.02 - 0.11, p=0.003) and calprotectin ({beta}=0.001, 0.0002 - 0.002, p=0.013). CRP was associated with AUC ({beta}=0.13, 95% CI 0.06 - 0.21, p=0.001) and Cmax ({beta}=0.12, 95% CI 0.05 - 0.21, p=0.002). Calprotectin ({beta}=0.12, 95% CI 0.04 - 0.20, p=0.003) and AAT ({beta}=0.09, 95% CI 0.02 - 0.15, p=0.008) were associated with a higher R-PZQ/S-PZQ AUC ratio, while CRP was not (p=0.38).
ConclusionElevated intestinal inflammatory markers were associated with increased Tmax, indicating reduced rate of absorption and relative increase in exposure to the active R-enantiomer. Systemic inflammation was associated with higher Cmax and AUC, implying increased exposure to PZQ. This is the first report linking alterations in praziquantel pharmacokinetics to EED markers and systemic inflammation.
Author summarySchistosomiasis, also known as bilharzia, affects approximately 240 million people in 79 countries with children in Africa bearing almost 50% of the burden. Praziquantel (PZQ), an oral drug, is the only widely available treatment for the disease. However, some studies have reported differences in pharmacokinetics and efficacy of PZQ across geographical locations suggesting environmental factors to affect drug response. We hypothesized that environmental enteric dysfunction, a disorder of altered intestinal function, may affect absorption and metabolism of PZQ because of the damage it inflicts on the intestinal mucosa, and subsequent systemic inflammation due to leakage of intestinal contents, a process referred to as "microbial translocation". Our findings indicate that markers of intestinal inflammation were associated with reduced rate of absorption while systemic inflammation was associated with increased plasma concentrations and overall exposure to PZQ. The reduced rate of absorption may result from destruction of the intestinal absorptive surface while increased plasma concentration and exposure may be due to reduced activity of PZQ-metabolizing enzymes in the liver. These observations could inform approaches for optimizing the effectiveness of PZQ by accounting for inflammation. This has implications for the use of PZQ as an effective control strategy and subsequent elimination of schistosomiasis by 2030, in line with World Health Organization targets.
Related
- Impact of praziquantel treatment and early reinfection patterns in a mixed Schistosoma mansoni and Schistosoma haematobium infection focus in the Democratic Republic of Congo
- Inflammation-Related Biomarkers Linking Environmental Chemical Mixtures and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Population-Based Study from NHANES 1999-2020
- Environmental PFOA exposure and the risk of metabolic dysfunction-associated steatotic liver disease: An integrated computational toxicology and multi-omics study
- Population pharmacokinetics of vancomycin in patients with liver dysfunction
- CSF pharmacokinetics-pharmacodynamics of linezolid in critically brain injured patients, with or without central nervous system healthcare-associated infection. The PK-Pop-LCR Study: A Multicentre Pharmacokinetics and Pharmacodynamics Population Study
BibTeX
@misc{edielu2026markers,
title = {{Markers of environmental enteric dysfunction are associated with changes in pharmacokinetics of praziquantel in preschool age children with Schistosoma mansoni infection in Albertine region of Uganda}},
author = {A. Edielu and B. Obura and P. A. Mawa and M. J. Holland and E. L. Webb and A. M. Elliott and G. K. Ayebazibwe and H. W. Wu and N. Mancini and F. C. Fischer and S. Colt and M. A. Barry and W. Hope and C. Waitt and J. F. Friedman and A. L. Bustinduy},
howpublished = {medRxiv},
year = {2026},
month = sep,
doi = {10.64898/2026.09.02.26362031},
url = {https://www.medrxiv.org/content/10.64898/2026.09.02.26362031v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - Markers of environmental enteric dysfunction are associated with changes in pharmacokinetics of praziquantel in preschool age children with Schistosoma mansoni infection in Albertine region of Uganda
AU - A. Edielu
AU - B. Obura
AU - P. A. Mawa
AU - M. J. Holland
AU - E. L. Webb
AU - A. M. Elliott
AU - G. K. Ayebazibwe
AU - H. W. Wu
AU - N. Mancini
AU - F. C. Fischer
AU - S. Colt
AU - M. A. Barry
AU - W. Hope
AU - C. Waitt
AU - J. F. Friedman
AU - A. L. Bustinduy
PY - 2026
DA - 2026/09/02
PB - medRxiv
DO - 10.64898/2026.09.02.26362031
UR - https://www.medrxiv.org/content/10.64898/2026.09.02.26362031v1
AB - IntroductionPraziquantel (PZQ) is the only widely available chemotherapy that is effective against all species of schistosomes. Environmental enteric dysfunction (EED) is an acquired intestinal disorder of altered gut function whose effect on drug pharmacokinetics has not been directly explored. MethodsPreschool-age children infected with S. mansoni were randomized to receive 40mg/kg or 80mg/kg of crushed PZQ tablets. Plasma PZQ concentrations were quantified using ultra-high performance liquid chromatography mass spectrometry. Maximum concentration (Cmax), time to Cmax (Tmax) and area under the curve (AUC) of PZQ were calculated. Biomarkers of intestinal inflammation (stool calprotectin), epithelial damage (plasma Intestinal Fatty Acid Binding Protein (IFABP)), permeability (urine lactulose:mannitol (LM) ratio and alpha-1 antitrypsin (AAT)), microbial translocation (plasma Endotoxin core antibodies (EndoCAb), systemic inflammation (plasma C-reactive protein (CRP)), and presence of faecal occult blood (FOB) were measured. Using linear regression, we assessed association of AUC, Cmax, Tmax and R- to S-PZQ exposure with each biomarker, adjusting for dose, age, and sex. ResultsOf the 184 participants included in the final analysis, 91 received 40mg/kg and 93 received 80mg/kg of PZQ. The Tmax was associated with LM ratio ({beta}=0.06, 95% CI 0.02 - 0.11, p=0.003) and calprotectin ({beta}=0.001, 0.0002 - 0.002, p=0.013). CRP was associated with AUC ({beta}=0.13, 95% CI 0.06 - 0.21, p=0.001) and Cmax ({beta}=0.12, 95% CI 0.05 - 0.21, p=0.002). Calprotectin ({beta}=0.12, 95% CI 0.04 - 0.20, p=0.003) and AAT ({beta}=0.09, 95% CI 0.02 - 0.15, p=0.008) were associated with a higher R-PZQ/S-PZQ AUC ratio, while CRP was not (p=0.38). ConclusionElevated intestinal inflammatory markers were associated with increased Tmax, indicating reduced rate of absorption and relative increase in exposure to the active R-enantiomer. Systemic inflammation was associated with higher Cmax and AUC, implying increased exposure to PZQ. This is the first report linking alterations in praziquantel pharmacokinetics to EED markers and systemic inflammation. Author summarySchistosomiasis, also known as bilharzia, affects approximately 240 million people in 79 countries with children in Africa bearing almost 50% of the burden. Praziquantel (PZQ), an oral drug, is the only widely available treatment for the disease. However, some studies have reported differences in pharmacokinetics and efficacy of PZQ across geographical locations suggesting environmental factors to affect drug response. We hypothesized that environmental enteric dysfunction, a disorder of altered intestinal function, may affect absorption and metabolism of PZQ because of the damage it inflicts on the intestinal mucosa, and subsequent systemic inflammation due to leakage of intestinal contents, a process referred to as "microbial translocation". Our findings indicate that markers of intestinal inflammation were associated with reduced rate of absorption while systemic inflammation was associated with increased plasma concentrations and overall exposure to PZQ. The reduced rate of absorption may result from destruction of the intestinal absorptive surface while increased plasma concentration and exposure may be due to reduced activity of PZQ-metabolizing enzymes in the liver. These observations could inform approaches for optimizing the effectiveness of PZQ by accounting for inflammation. This has implications for the use of PZQ as an effective control strategy and subsequent elimination of schistosomiasis by 2030, in line with World Health Organization targets.
ER -